Acute promyelocytic leukemia cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 2: Line 2:
{{Acute promyelocytic leukemia}}
{{Acute promyelocytic leukemia}}


{{CMG}} {{shyam}}
{{CMG}}; {{AE}} {{shyam}}; {{GRR}} {{Nat}}


==Overview==
==Overview==
A limited number of cost-effective studies have been done. In summary, these studies showed that all-''trans'' retinoic acid-based therapy is more cost effective than chemotherapy.
A limited number of cost-effective studies have been done. In summary, these studies showed that all-''[[trans]]'' [[retinoic acid]]-based [[therapy]] is more cost effective than [[chemotherapy]].


==Cost-effectiveness of therapy==
==Cost-effectiveness of therapy==
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective [[analysis]] studied the costs of [[therapy]].
*The combination of all-''trans'' retinoic acid plus idarubicin was more cost-effective than the combination of all-''trans'' retinoic acid plus cytarabine plus additional chemotherapy.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
*The combination of all-''[[trans]]'' [[retinoic acid]] plus [[idarubicin]] was more cost-effective than the combination of all-''[[trans]]'' [[retinoic acid]] plus [[cytarabine]] plus additional [[chemotherapy]].<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
**The incremental cost-effective ratio for all-''trans'' retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
**The [[Incremental cost-effectiveness ratio|incremental cost-effective ratio]] for all-''[[trans]]'' [[retinoic acid]] plus [[idarubicin]] was $2933 per life year saved and $3122 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
*The combination of all-''trans'' retinoic acid plus arsenic trioxide was more cost-effective than all-''trans'' retinoic acid plus idarubicin.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
*The combination of all-''[[trans]]'' [[retinoic acid]] plus [[arsenic]] trioxide was more cost-effective than all-''[[trans]]'' [[retinoic acid]] plus [[idarubicin]].<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
**The incremental cost-effective ratio for all-''trans'' retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>
**The [[incremental cost-effective ratio]] for all-''[[trans]]'' [[retinoic acid]] plus [[arsenic trioxide]] was $4512 per life year saved and $5614 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645  }} </ref>


==References==
==References==

Latest revision as of 13:13, 11 April 2019

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia cost-effectiveness of therapy

CDC on Acute promyelocytic leukemia cost-effectiveness of therapy

Acute promyelocytic leukemia cost-effectiveness of therapy in the news

Blogs on Acute promyelocytic leukemia cost-effectiveness of therapy

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

A limited number of cost-effective studies have been done. In summary, these studies showed that all-trans retinoic acid-based therapy is more cost effective than chemotherapy.

Cost-effectiveness of therapy

A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.

References

  1. 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.

Template:WH Template:WS